loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Oxprenolol

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Oxprenolol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Actimed gets US patent for ACM-001 & Canadian patent for ACM-002
    Actimed gets US patent for ACM-001 & Canadian patent for ACM-002

    14 Oct 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=143238&sid=2

    PHARMABIZ
    14 Oct 2021
    Share Share
    Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM-002
    Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM-002

    30 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/actimed-therapeutics-granted-broad-us-patent-covering-rights-to-acm002-s-oxprenolol-for-treating-cancer-cachexia-301181585.html

    PRNEWSWIRE
    30 Nov 2020
    Share Share